Trial of Cinpanemab in Early Parkinson’s Disease

• Published in: The New England journal of medicine Vol. 387; no. 5; pp. 408 - 420
• Main Authors: Lang, Anthony E., Siderowf, Andrew D., Macklin, Eric A., Poewe, Werner, Brooks, David J., Fernandez, Hubert H., Rascol, Olivier, Giladi, Nir, Stocchi, Fabrizio, Tanner, Caroline M., Postuma, Ronald B., Simon, David K., Tolosa, Eduardo, Mollenhauer, Brit, Cedarbaum, Jesse M., Fraser, Kyle, Xiao, James, Evans, Karleyton C., Graham, Danielle L., Sapir, Inbal, Inra, Jennifer, Hutchison, R. Matthew, Yang, Minhua, Fox, Tara, Budd Haeberlein, Samantha, Dam, Tien
• Format: Journal Article
• Language: English
• Published: Boston Massachusetts Medical Society 04.08.2022
• Subjects: Aging; Aging General; Clinical trials; Cognitive ability; Computed tomography; Coronaviruses; COVID-19; Dopamine; Dopamine transporter; Geriatrics; Intravenous administration; Laboratories; Magnetic resonance imaging; Medical research; Monoclonal antibodies; Movement disorders; Neostriatum; Neurodegenerative diseases; Neurology; Neurosurgery; Parkinson Disease; Parkinson's disease; Pharmacokinetics; Placebos; Rhinopharyngitis; Single photon emission computed tomography; Synuclein

AbstractBackgroundAggregated α-synuclein plays an important role in Parkinson’s disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson’s disease.MethodsIn a 52-week, multicenter, double-blind,...